KalVista Pharmaceuticals (KALV) EPS (Basic) Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -100.00% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -79.34% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 61.11% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3,856.63% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -7.78% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,207.14% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -28.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -28.74% |
| Apr 30, 2025 | 7.48% |
| Oct 31, 2024 | -13.75% |
| Jul 31, 2024 | -17.57% |
| Apr 30, 2024 | -42.67% |
| Jan 31, 2024 | -12.00% |
| Oct 31, 2023 | 11.11% |
| Jul 31, 2023 | 21.28% |
| Apr 30, 2023 | 23.47% |
| Jan 31, 2023 | 18.48% |
| Oct 31, 2022 | -12.50% |
| Jul 31, 2022 | -42.42% |
| Apr 30, 2022 | -46.27% |
| Jan 31, 2022 | -64.29% |
| Oct 31, 2021 | -37.93% |
| Jul 31, 2021 | -8.20% |
| Apr 30, 2021 | -81.08% |
| Jan 31, 2021 | -7.69% |
| Oct 31, 2020 | -75.76% |
| Jul 31, 2020 | -45.24% |
| Apr 30, 2020 | 24.49% |
| Jan 31, 2020 | -126.09% |
| Oct 31, 2019 | -50.00% |
| Jul 31, 2019 | 10.64% |
| Apr 30, 2019 | -716.67% |
| Jan 31, 2019 | 53.06% |
| Oct 31, 2018 | 56.00% |
| Jul 31, 2018 | 7.84% |
| Apr 30, 2018 | 86.05% |
| Jan 31, 2018 | 52.43% |
| Oct 31, 2017 | 91.64% |
| Jul 31, 2017 | 92.34% |
| Mar 31, 2016 | 96.61% |
| Dec 31, 2015 | 96.92% |
| Sep 30, 2015 | 96.77% |
| Jun 30, 2015 | 90.61% |
| Mar 31, 2015 | -68.11% |